Novo Nordisk AS (XTER:NOV) EV-to-EBITDA : 13.15 (As of May. 20, 2025)

View and export this data going back to 1999. Start your Free Trial

What is Novo Nordisk AS EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Novo Nordisk AS's enterprise value is €271,601 Mil. Novo Nordisk AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €20,658 Mil. Therefore, Novo Nordisk AS's EV-to-EBITDA for today is 13.15.

The historical rank and industry rank for Novo Nordisk AS's EV-to-EBITDA or its related term are showing as below:

XTER:NOV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.03 Med: 18.53 Max: 36.14
Current: 13.15

During the past 13 years, the highest EV-to-EBITDA of Novo Nordisk AS was 36.14. The lowest was 11.03. And the median was 18.53.

XTER:NOV's EV-to-EBITDA is ranked better than
51.92% of 730 companies
in the Drug Manufacturers industry
Industry Median: 13.575 vs XTER:NOV: 13.15

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-20), Novo Nordisk AS's stock price is €58.97. Novo Nordisk AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €3.148. Therefore, Novo Nordisk AS's PE Ratio (TTM) for today is 18.73.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Novo Nordisk AS EV-to-EBITDA Historical Data

The historical data trend for Novo Nordisk AS's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS EV-to-EBITDA Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBITDA

Get a 7-Day Free Trial

16.87

26.10

27.51

27.12

20.74

Novo Nordisk AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBITDA	Get a 7-Day Free Trial															31.63	33.40	25.15	20.74	14.05

Competitive Comparison of Novo Nordisk AS's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's EV-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Novo Nordisk AS EV-to-EBITDA Calculation

Novo Nordisk AS's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	271600.567	/	20657.539
	=	13.15

Novo Nordisk AS's current Enterprise Value is €271,601 Mil.
Novo Nordisk AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €20,658 Mil.

Novo Nordisk AS (XTER:NOV) EV-to-EBITDA Explanation

Novo Nordisk AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	58.97	/	3.148
	=	18.73

Novo Nordisk AS's share price for today is €58.97.
Novo Nordisk AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.148.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Novo Nordisk AS EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (XTER:NOV) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.